Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma

AM Griesinger, AJ Calzadilla, E Grimaldo… - Clinical Cancer …, 2024 - AACR
Purpose: There are no effective treatment strategies for children with highest-risk posterior
fossa group A ependymoma (PFA). Chromosome 1q gains (1q+) are present in …

No safe harbors for recurrent posterior fossa group A ependymoma: A time for change in risk assignment?

JR Hansford, DD Eisenstat - Neuro-oncology, 2023 - academic.oup.com
Editorial 1869 treatment-resistant, undifferentiated neuroepithelial progenitor-like cell (UEC-
A) group that is selected for the high-risk patients at relapse. Furthermore, IHC scoring of …

Developing targeted therapies for pediatric PFA ependymoma

AL Jenseit - 2024 - archiv.ub.uni-heidelberg.de
PFA ependymomas are highly aggressive brain tumors typically arising in young children
(median age 3 years) and characterized by a poor outcome (10-year OS< 60%). Standard of …

Glioma

M Weller, PY Wen, SM Chang, L Dirven… - Nature Reviews …, 2024 - nature.com
Gliomas are primary brain tumours that are thought to develop from neural stem or
progenitor cells that carry tumour-initiating genetic alterations. Based on microscopic …

[HTML][HTML] MedLink®, LLC

RJ Packer - medlink.com
Medulloblastoma is the most common malignant childhood brain tumor. There has been a
marked improvement in overall survival for patients with this tumor, but a major challenge …

Clinically relevant molecular hallmarks of PFA ependymomas display intratumoral heterogeneity and correlate with tumor morphology

S Gödicke, C Kresbach, M Ehlert, D Obrecht… - Acta …, 2024 - Springer
Posterior fossa type A (PF-EPN-A, PFA) ependymoma are aggressive tumors that mainly
affect children and have a poor prognosis. Histopathology shows significant intratumoral …